Electromed Reports Record Q3 Revenue and Profit Growth

Electromed ( (ELMD) ) just unveiled an announcement.

Electromed, Inc. reported record financial results for its fiscal 2026 third quarter ended March 31, 2026, with net revenue up 18.4% year over year to $18.6 million, driven by an 18.6% gain in its core direct homecare business. Revenue growth, higher net revenue per device and strong sales force productivity helped lift gross profit to $14.6 million and pushed operating income up 76.0% to $3.8 million, or 20.3% of net revenues.

Net income for the quarter rose 58.8% to a record $3.0 million, or $0.35 per diluted share, marking Electromed’s 14th consecutive quarter of year-over-year revenue and profit growth. Management highlighted completed manufacturing optimization, expanded sales and fulfillment capacity, and broad payer coverage as key factors positioning the company to capture more of the underserved bronchiectasis and airway clearance markets, while maintaining a debt-free balance sheet, $17.0 million in cash and robust working capital.

The most recent analyst rating on (ELMD) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Electromed stock, see the ELMD Stock Forecast page.

Spark’s Take on ELMD Stock

According to Spark, TipRanks’ AI Analyst, ELMD is a Outperform.

ELMD scores well on financial strength (expanding profitability, strong returns, and a near debt-free balance sheet) and supportive earnings-call guidance centered on double-digit growth and operating leverage. The score is tempered by a weaker short-term technical backdrop and a relatively high P/E with no dividend yield provided, plus the noted recent slowdown in TTM revenue growth and past cash-flow volatility.

To see Spark’s full report on ELMD stock, click here.

More about Electromed

Electromed, Inc. is a medical device company that manufactures, markets and sells airway clearance therapy products, including its flagship SmartVest Airway Clearance System, for patients with compromised pulmonary function. Founded in 1992 and headquartered in New Prague, Minnesota, the company focuses on the U.S. homecare market while also serving hospitals and distributors in the airway clearance segment.

Electromed positions itself as a leader in innovative airway clearance technologies, leveraging a direct homecare sales force and broad payer coverage, with 86% of covered lives in the United States under contract for its therapies. The company emphasizes education and awareness in the underserved bronchiectasis market and operates with a debt-free balance sheet, strong working capital and a strategy centered on profitable growth.

Average Trading Volume: 49,514

Technical Sentiment Signal: Buy

Current Market Cap: $222.9M

For a thorough assessment of ELMD stock, go to TipRanks’ Stock Analysis page.